---
title: "Analyst Reiterates Buy on West as Biologics-Driven Double-Digit Growth, Margin Upside and Conservative Outlook Signal Further Upside Potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293625778.md"
description: "William Blair analyst Matt Larew reiterated a Buy rating on West Pharmaceutical Services (WST) on July 15, citing double-digit organic growth driven by biologics, improved margins, and conservative full-year outlooks offering upside potential. TD Cowen also maintained a Buy rating with a $410 price target."
datetime: "2026-07-23T13:15:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293625778.md)
  - [en](https://longbridge.com/en/news/293625778.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293625778.md)
generator: "portal-rs"
---

# Analyst Reiterates Buy on West as Biologics-Driven Double-Digit Growth, Margin Upside and Conservative Outlook Signal Further Upside Potential

William Blair analyst Matt Larew has maintained their bullish stance on WST stock, giving a Buy rating on July 15.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Matt Larew has given his Buy rating due to a combination of factors, including West’s ability to deliver another quarter of solid double-digit organic growth, driven largely by strong momentum in its biologics franchise. He highlights that both GLP and non-GLP products are contributing meaningfully, with non-GLP offerings growing at a high-teens rate and GLP-1–related products already representing a notable share of total company revenue.

Larew also points to the company’s top-line results, which exceeded both his and the Street’s expectations, as well as the improved margins and earnings per share performance that underscore operating leverage. In his view, the revised full-year outlook retains an element of conservatism despite a strong first half, leaving room for upside if demand for West’s elastomer and West Vantage solutions continues to track ahead of plan.

According to TipRanks, Larew is a 4-star analyst with an average return of 10.0% and a 53.13% success rate. Larew covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Option Care Health, and Repligen.

In another report released on July 15, TD Cowen also maintained a Buy rating on the stock with a $410.00 price target.

### Related Stocks

- [WST.US](https://longbridge.com/en/quote/WST.US.md)
- [NA.US](https://longbridge.com/en/quote/NA.US.md)
- [OPCH.US](https://longbridge.com/en/quote/OPCH.US.md)
- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)

## Related News & Research

- [Mitsubishi UFJ Asset Management Co. Ltd. Makes New $67.58 Million Investment in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/296465296.md)
- [Is West Pharmaceutical Services (WST) Undervalued After Its Run to $349.42?](https://longbridge.com/en/news/295995196.md)
- [Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296585791.md)
- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2](https://longbridge.com/en/news/296129489.md)
- [Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset](https://longbridge.com/en/news/296129081.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**